Cargando…
Gene Therapy Targeting PCSK9
The last decades of research in cardiovascular prevention have been characterized by successful bench-to-bedside developments for the treatment of low-density lipoprotein (LDL) hypercholesterolemia. Recent examples include the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) with...
Autores principales: | Katzmann, Julius L., Cupido, Arjen J., Laufs, Ulrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781734/ https://www.ncbi.nlm.nih.gov/pubmed/35050192 http://dx.doi.org/10.3390/metabo12010070 |
Ejemplares similares
Ejemplares similares
-
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
por: Katzmann, Julius L., et al.
Publicado: (2020) -
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Schulz, Rainer, et al.
Publicado: (2015) -
Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
por: Glerup, Simon, et al.
Publicado: (2017) -
Why doesn’t high cholesterol hurt?
por: Katzmann, Julius L., et al.
Publicado: (2019) -
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk
por: Katzmann, Julius L., et al.
Publicado: (2022)